Maxim Group
http://www.maximgrp.com/Maxim Group is a financial services firm that provides investment banking, asset management, research, and sales & trading to a diverse range of corporate clients, institutional investors and high net worth individuals.
The firm’s research division uses fundamental research and a “bottom up” approach to making investment recommendations. Maxim’s research analysts focus on under-covered, small- to mid-cap names in a variety of sectors including healthcare, technology, retail and others.
View Older Stories View More Recent Stories
-
Interpace Diagnostics Announces Pricing of Public Offering to Raise $3.6 Million
-
Interpace Diagnostics (IDXG) Plans Public Offering of Common Stock
-
Interpace Diagnostics Announces Proposed Public Offering of Common Stock
-
Maxim Group Downgrades Galena Biopharma (GALE) to Hold
-
Athersys Announces Closing of Public Offering of Common Stock
-
Provectus Biopharmaceuticals, Inc. Announces Commencement Of Rights Offering To Existing Stockholders And Holders Of Certain Warrants
-
Cerecor (CERC) Reports ATM Equity Offering Program
-
Cerecor Announces At-the-Market Equity Offering Program
-
Athersys (ATHX) Prices 19.8M Shares at $1.01
-
Athersys Announces Pricing of Public Offering of Common Stock
-
KeyW Holding (KEYW) 8.5M Share Offering Prices at $10.50
-
KeyW Announces Pricing of Public Offering of Common Stock
-
Maxim Group Starts Mateon Therapeutics (MATN) at Buy
-
KeyW (KEYW) Announces 8.5M Public Offering of Common Stock
-
KeyW Announces Public Offering of Common Stock
-
Pre-Open Stock Movers 01/26: (AVGR) (CHTR) (MGI) Higher; (MAT) (MCK) (FFIV) Lower (more...)
-
Maxim Group Upgrades Capnia (CAPN) to Buy, $5 PT
-
Adamis Pharmaceuticals (ADMP): EpiPen Wars Emerge - Maxim
-
Maxim Group Upgrades ADMA Biologics (ADMA) to Buy
-
CytoSorbents (CTSO) PT Raised to $10 at Maxim Group
-
Milestone Scientific Inc. Announces Partial Exercise of Over-Allotment Option
-
Interpace Diagnostics (IDXG) Enters $4M Common Stock Securities Purchase Agreement
-
Interpace Diagnostics Announces $4.0 Million Registered Direct Offering of Common Stock
-
Interpace Diagnostics (IDXG) to Offer 855K Common Shares and Warrants
-
Amedica (AMDA) Prices $4.5M Offering of Common Stock and Warrants
-
Amedica Announces Pricing of Public Offering to Raise $4.5 Million
-
Maxim Group Starts BioLife Solutions (BLFS) at Buy, $3 PT
-
Amedica (AMDA) Plans Offering of Common Stock and Warrants
-
Amedica Announces Proposed Public Offering of Common Stock and Warrants
-
Medley Management Inc. Announces Closing of $34.5 Million Medley LLC Public Offering of 7.25% Notes Due 2024
-
PlacementTracker Publishes 2016 Private Placement Market League Tables
-
Kite Pharma (KITE): China JV Could Bring $140 In Royalties - Maxim
-
AEterna Zentaris (AEZS) PT Raised to $10 at Maxim Group; Macrilen Returns to Model
-
PIPE Deals Positioned to Soar in 2017 with Trump Deregulation Gift
-
Medley Management Inc. Announces Upsizing and Pricing of $30 Million Medley LLC Public Offering of 7.25% Notes Due 2024
-
Medley Management Inc. Announces Public Offering of Medley LLC Notes Due 2024
-
Maxim Group Downgrades Teva Pharma (TEVA) to Hold
-
COPsync Announces $1.15 Million Registered Direct Offering
-
Interpace Diagnostics Announces $4.2 Million Registered Direct Offering of Common Stock
-
Interpace Diagnostics (IDXG) Discloses Private Placement of 375K Shares at $6.75/Share
-
Teva Pharma (TEVA) PT Trimmed to $49 at Maxim Group; 'Buy' Maintained
-
Maxim Group Reiterates Bullish View on Galena Biopharma (GALE) as GALE-401 is Going Pivotal in 2017
-
Prima Biomed (PBMD) PT Lowered to $7 at Maxim Group, Buy Maintained as LAG-3 + Keytruda Moves to Higher Dose
-
Milestone Scientific Inc. Announces Closing of Public Offering of Common Stock and Warrants
-
Maxim Group Starts Tsakos Energy (TNP) at Buy
-
Maxim Group Starts Nordic American Tanker Shipping Ltd. (NAT) at Sell
-
Maxim Group Starts DHT Holdings (DHT) at Buy
-
Maxim Group Starts Pyxis Tankers (PXS) at Buy
-
Interpace Diagnostics (IDXG) Enters Agreement with a Single Investor to purchase 2M Shares of Common Stock at $0.53 Per Share
-
Interpace Diagnostics Announces $1.9 Million Registered Direct Offering of Common Stock


